货号:A397911
同义名:
PARP-IN-1; 3-(Aminocarbonyl) Aniline
3-Aminobenzamide是一种强效的PARP抑制剂,在CHO细胞中IC50值<50 nM,并且是氧化应激诱导的肌细胞功能障碍的介导因子。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | PARP ↓ ↑ | PARP1 ↓ ↑ | PARP2 ↓ ↑ | PARP3 ↓ ↑ | 其他靶点 | 纯度 | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PJ34 HCl |
++
PARP, EC50: 20 nM |
99%+ | |||||||||||||||||
| Rucaparib phosphate |
++++
PARP, Ki: 1.4 nM |
99%+ | |||||||||||||||||
| 3-Aminobenzamide |
++
PARP, IC50: <50 nM |
98% | |||||||||||||||||
| AZD-2461 | ✔ | 99%+ | |||||||||||||||||
| BGP-15 | ✔ | 99%+ | |||||||||||||||||
| NU1025 |
+
PARP, IC50: 400 nM |
98% | |||||||||||||||||
| Benzamide |
+
PARP, IC50: 3.3 μM |
98% | |||||||||||||||||
| Picolinamide |
+
PARP, IC50: 95 μM |
98% | |||||||||||||||||
| AG14361 |
+++
PARP1, Ki: <5 nM |
98+% | |||||||||||||||||
| Iniparib | ✔ | 98% | |||||||||||||||||
| Talazoparib |
++++
PARP1, IC50: 0.57 nM |
99%+ | |||||||||||||||||
| NMS-P118 |
++
PARP1, Kd: 0.009 μM |
97% | |||||||||||||||||
| UPF 1069 |
+
PARP1, IC50: 8.0 μM |
++
PARP2, IC50: 0.3 μM |
98% | ||||||||||||||||
| A-966492 |
++++
PARP1, Ki: 1 nM PARP1, EC50: 1 nM |
+++
PARP2, Ki: 1.5 nM |
99%+ | ||||||||||||||||
| Veliparib |
++
PARP1, Ki: 5.2 nM |
+++
PARP2, Ki: 2.9 nM |
98% | ||||||||||||||||
| Niraparib tosylate |
+++
PARP1, IC50: 3.8 nM |
+++
PARP2, IC50: 2.1 nM |
99%+ | ||||||||||||||||
| Stenoparib |
++++
PARP1, IC50: 1 nM |
++++
PARP2, IC50: 1.2 nM |
98% | ||||||||||||||||
| Olaparib |
+++
PARP1, IC50: 5 nM |
++++
PARP2, IC50: 1 nM |
98% | ||||||||||||||||
| Niraparib |
+++
PARP1, IC50: 3.8 nM |
+++
PARP2, IC50: 2.1 nM |
98% | ||||||||||||||||
| ME0328 |
+
PARP1, IC50: 6.3 μM |
+
PARP3, IC50: 0.89 μM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | The nuclear enzyme poly(ADP-ribose) polymerase (PARP) plays an important role in the repair of DNA strand breaks, including those induced by radiation, thus making it a potential target for radiosensitizers. INO-1001 is a novel and potent inhibitor of PARP. INO-1001 at a concentration of 0.05 μM resulted in approximately 50% inhibition of PARP activity in CHO cells after 30 minutes treatment. And concentrations of 1 μM or greater resulted in more than 95% inhibition of the enzyme. Exponentially growing CHO cells were treated with 10 μM INO-1001 starting 30 min. prior to irradiation. INO-1001 significantly sensitized CHO cells to radiation. The initial slope of the survival curve for drug treated and irradiated cultures was greater than radiation alone. The enhancement ratio (ER) at 10% survival was 1.6. A similar radiosensitizing effect was observed in a murine tumor cell line with an ER of 1.7. The fibroblasts were also sensitized by the drug treatment with an ER of 1.4[2]. Immediately after CCI (controlled cortical impact) or sham-injury mice received either INO-1001 (1.6 mg/kg) or vehicle via intracerebral injection (5 microl over 5 min) in a randomized fashion. Local treatment with INO-1001 preserved brain NAD+ levels 2 h after CCI. In the Morris water maze, treatment with INO-1001 reduced the latency to find the hidden platform and increased the time spent in the target quadrant versus vehicle after CCI[3]. |
| Concentration | Treated Time | Description | References | |
| HSG cells | 10 µM | 30 minutes | Inhibit PARP1 activity, reduce H2O2-induced Ca2+ increase | Nat Commun. 2013;4:1515. |
| CHO-K1 cells | 7 mM | 72 hours | Induced centrosome amplification and chromosomal aneuploidy | Int J Mol Sci. 2023 Dec 27;25(1):383. |
| H9C2 cells | 20 µM | 12 hours | Inhibited DOX-induced PARylation, reduced cardiomyocyte apoptosis and mitochondrial damage | Acta Pharm Sin B. 2019 Jul;9(4):782-793. |
| Human intestinal organoids | 20 mM | 12 hours | Inhibited PARP1-dependent parthanatos and reduced cell death | Cell Death Discov. 2024 Jul 31;10(1):345. |
| HeLa cells | 10 mM | 20 hours | To investigate the effect of 3-aminobenzamide on cell surface peptidase activity in UVB-induced apoptotic HeLa cells. Results showed that 3AB treatment significantly reduced cell surface peptidase activity in apoptotic cells. | Int J Mol Sci. 2012;13(3):2650-2675. |
| Neonatal rat cardiomyocytes | 500 µM | 24 hours | Inhibition of PARP-1 activity, attenuating isoprenaline-induced cardiomyocyte hypertrophy | Br J Pharmacol. 2015 Jun;172(11):2852-63. |
| Rice seedlings | 1 mM | 24 hours | 3-Aminobenzamide, as a PARP inhibitor, enhanced cold tolerance in rice seedlings by reducing NAD+ consumption and maintaining energy homeostasis. | Antioxidants (Basel). 2022 Dec 29;12(1):79. |
| Caco-2 cells | 20 mM | 6 hours | Inhibited PARP1-dependent parthanatos and reduced cell death | Cell Death Discov. 2024 Jul 31;10(1):345. |
| Immortalized MEF | 7 mM | 72 hours | Induced centrosome amplification but did not cause chromosomal aneuploidy | Int J Mol Sci. 2023 Dec 27;25(1):383. |
| U-937 cells | 5 µM | 8 hours | Evaluate the antileukemic potential of MAC681 in U-937 cells, showing induction of DNA damage and necroptotic-like cell death. | Biomark Res. 2024 May 4;12(1):47. |
| K-562 cells | 5 µM | 8 hours | Evaluate the antileukemic potential of MAC681 in K-562 cells, showing induction of DNA damage, mitochondrial dysfunction, and necroptotic-like cell death. | Biomark Res. 2024 May 4;12(1):47. |
| Rd2 organotypic retinal cultures | 10 nM | one week | Significantly reduced PARylation levels and photoreceptor cell death | Acta Neuropathol Commun. 2025 Apr 1;13(1):68. |
| Administration | Dosage | Frequency | Description | References | ||
| Rice | Rice seedlings | Foliar spray | 1 mM | Single treatment, 24 hours of cold stress | The combination of 3-aminobenzamide and OPCs significantly enhanced cold tolerance in rice seedlings by inhibiting PARP activity and enhancing ATPase activity to maintain energy homeostasis. | Antioxidants (Basel). 2022 Dec 29;12(1):79. |
| Rats | Haemorrhagic shock model | Intravenous injection | 10 mg/kg | Single dose 5 min prior to resuscitation | To evaluate the effects of 3-aminobenzamide on organ injury and dysfunction caused by haemorrhagic shock. Results showed that 3-aminobenzamide attenuated renal dysfunction, hepatocellular injury, and pancreatic injury. | Br J Pharmacol. 1999 Nov;128(6):1339-45 |
| Mice | TRPM2+/+ mice | Intraperitoneal injection | 20 mg/kg | Once, 1 hour before radiation | Inhibit PARP1 activity, reduce radiation-induced TRPM2 activation, significantly restore salivary gland fluid secretion | Nat Commun. 2013;4:1515. |
| BALB/C57 mice | Light-induced retinal damage model | Intraperitoneal injection | 20 mg/kg | Consecutive 7 days | To evaluate the protective effect of 3-Aminobenzamide on light-induced retinal damage. Results showed that 3-Aminobenzamide significantly alleviated light-induced structural and functional damage to the retina. | Cell Commun Signal. 2020 Feb 17;18(1):27 |
| SD rats | Abdominal aortic constriction (AAC) surgery-induced cardiac hypertrophy model | Intraperitoneal injection | 20 mg/kg | Once daily for 6 weeks | Pre-treatment with 3AB alleviated AAC-induced translocation of nuclear HMGB1 protein, cardiac hypertrophy, and heart dysfunction | Acta Pharmacol Sin. 2019 May;40(5):589-598 |
| Mice | Necrotizing enterocolitis model | Intraperitoneal injection | 20 μg/g | 4 consecutive days | Inhibited parthanatos and alleviated intestinal epithelial damage and inflammatory response | Cell Death Discov. 2024 Jul 31;10(1):345. |
| Sprague-Dawley rats | DOX-induced cardiomyopathy model | Intraperitoneal injection | 40 mg/kg/day | Once daily for 7 days | Alleviated DOX-induced cardiac apoptosis, mitochondrial dysfunction and heart dysfunction | Acta Pharm Sin B. 2019 Jul;9(4):782-793. |
| C57BL/6 mice | C1498 cell xenograft model | Subcutaneous injection | 5 µM | Single injection, observed for one week | Evaluate the immunogenic potential of MAC681 in vivo, showing that MAC681-treated cells could generate an immunogenic vaccine and significantly reduce tumor growth. | Biomark Res. 2024 May 4;12(1):47. |
| Female rats | Takotsubo syndrome model | Intraperitoneal injection | 50 mg/kg | Single dose, lasting 24 hours | Pretreatment with 3-aminobenzamide (a PARP-1 inhibitor) attenuates negative inotropic changes | JACC Basic Transl Sci. 2018 Apr 18;3(2):213-226 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
7.34mL 1.47mL 0.73mL |
36.72mL 7.34mL 3.67mL |
73.45mL 14.69mL 7.34mL |
|
| CAS号 | 3544-24-9 |
| 分子式 | C7H8N2O |
| 分子量 | 136.15 |
| SMILES Code | O=C(N)C1=CC=CC(N)=C1 |
| MDL No. | MFCD00007989 |
| 别名 | PARP-IN-1; 3-(Aminocarbonyl) Aniline; 3-Carboxamidoaniline; 3-AB; 3-ABA |
| 运输 | 蓝冰 |
| InChI Key | GSCPDZHWVNUUFI-UHFFFAOYSA-N |
| Pubchem ID | 1645 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, room temperature |
| 溶解方案 |
H2O: 10 mg/mL(73.45 mM) 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1